# Rituximab

## Mabthera inj 100mg/10mL

##### 臨採

| TAH Drug Code      | [IMAB1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IMAB1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment, after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion, start at 100 mg/hour; if there is no infusion-related reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin’s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1, then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation), but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Hypersensitivity to rituximab or murine proteins. Pregnancy, lactation. Active hepatits B disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Fever, chills or rigor, flushing, angioedema, nausea, urticaria/rash, fatigue, headache, pruritus, dyspnea, throat irritation, rhinitis, vomiting. Cardiovascular: Hypertension (all grades, 6%; grades 3 and 4, 1% ), Hypotension (all grades, 10%; grades 3 and 4, 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% ), Diarrhea (10% ), Nausea (23% ), Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma, all grades, 26%; grades 3 and 4, 1%; rheumatoid arthritis, 2% ), Dizziness (all grades, 10%; grades 3 and 4, 1% ), Headache (all grades, 19%; grades 3 and 4, 1% ), Sensory neuropathy (30% ) Other: Fever (all grades, 53%; grades 3 and 4, 1% ), Shivering (all grades, 33%; grades 3 and 4, 3% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rituximab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## MABTHERA infusion 500mg/50mL

##### 臨採

| TAH Drug Code      | [IMAB5](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IMAB5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of patients with relapsed or chemoresistant indolent B-cell non-Hodgkin's lymphoma. In combination with CHOP or other chemotherapy agents in the treatment of diffuse large B-cell lymphoma patients. In combination with CVP chemotherapy agents in the untreated advanced follicular B-cell non-Hodgkin's lymphoma. Treatment of patients with follicular lymphoma as maintenance treatment, after response to induction therapy. In combination with methotrexate for treatment of adults with active RA who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Dosing             | Administration rate (adult)- Initial infusion: Start infusion at a rate of 50 mg/hour; if there is no infusion-related reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour.- Subsequent infusions: If patient tolerated initial infusion, start at 100 mg/hour; if there is no infusion-related reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. [Low-grade or Follicular Non-Hodgkin’s Lymphoma (NHL)] 375 mg/m2 once weekly for 4 doses. Retreatment following disease progression: 375 mg/m2 once weekly for 4 doses. Maintenance therapy (in untreated patients with response to induction therapy): 375 mg/m2 every 2 months until relapse or for maximum duration of 2 years. Maintenance therapy (relapsed/refractory): 375 mg/m2 every 3 months until relapse or for maximum duration of 2 years. [Diffuse Large B-cell NHL] 375 mg/m2 on day 1 of each chemotherapy cycle for up to 8 doses in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, prednisone and vincristine) [Chronic Lymphocytic Leukaemia (CLL)] 375 mg/m2 on the day prior to chemotherapy in cycle 1, then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 in combination with chemotherapy. [Rheumatoid Arthritis (RA)] 500-1000 mg on days 1 and 15; subsequent courses may be administered every 24 weeks (or based on clinical evaluation), but no sooner than every 16 weeks. Premedication with methylprednisolone 100 mg IV is recommended 30 minutes prior to each rituximab dose. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Contraindications  | Hypersensitivity to rituximab or murine proteins. Pregnancy, lactation. Active hepatits B disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Fever, chills or rigor, flushing, angioedema, nausea, urticaria/rash, fatigue, headache, pruritus, dyspnea, throat irritation, rhinitis, vomiting. Cardiovascular: Hypertension (all grades, 6%; grades 3 and 4, 1% ), Hypotension (all grades, 10%; grades 3 and 4, 1% ) Dermatologic: Pruritus Gastrointestinal: Abdominal pain (14% ), Diarrhea (10% ), Nausea (23% ), Vomiting (10% ) Neurologic: Asthenia (non-Hodgkin's lymphoma, all grades, 26%; grades 3 and 4, 1%; rheumatoid arthritis, 2% ), Dizziness (all grades, 10%; grades 3 and 4, 1% ), Headache (all grades, 19%; grades 3 and 4, 1% ), Sensory neuropathy (30% ) Other: Fever (all grades, 53%; grades 3 and 4, 1% ), Shivering (all grades, 33%; grades 3 and 4, 3% )                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rituximab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## Truxima inj 500mg/50mL

##### 臨採

| TAH Drug Code      | [ITRU](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITRU)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | The treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL): Relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; OR Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; OR Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Chronic lymphoid leukemia: In combination for first-line treatment; OR in combination with fludarabine and cyclophosphamide; OR maintenance, following rituximab-containing chemotherapy. Granulomatosis with polyangiitis or Microscopic polyangiitis: In combination with glucocorticoids                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | Recommended Dose for Non-Hodgkin’s Lymphoma (NHL): The recommended dose is 375 mg/m2. Relapsed or Refractory, Low-Grade or Follicular, CD20-Positive, B-Cell NHL: Administer once weekly for 4 or 8 doses. Retreatment for Relapsed or Refractory, Low-Grade or Follicular, CD20Positive, B-Cell NHL: Administer once weekly for 4 doses. Previously Untreated, Follicular, CD20-Positive, B-Cell NHL: Administer on Day 1 of each cycle of chemotherapy, for up to 8 doses. In patients with complete or partial response, initiate TRUXIMA maintenance eight weeks following completion of a rituximab product in combination with chemotherapy. Administer TRUXIMA as a single-agent every 8 weeks for 12 doses. Non-progressing, Low-Grade, CD20-Positive, B-Cell NHL, after first-line CVP chemotherapy: Following completion of 6-8 cycles of CVP chemotherapy, administer once weekly for 4 doses at 6-month intervals to a maximum of 16 doses. First Infusion: Initiate infusion at a rate of 50 mg/hour. In the absence of infusion toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hour. Subsequent Infusions: Standard Infusion: Initiate infusion at a rate of 100 mg/hour. In the absence of infusion toxicity, increase rate by 100 mg/hour increments at 30-minute intervals, to a maximum of 400 mg/hour. Chronic lymphocytic leukemia: 375 mg/m2 on the day prior to fludarabine/cyclophosphamide in cycle 1, then 500 mg/m2 on day 1 (every 28 days) of cycles 2 to 6 (in combination with fludarabine and cyclophosphamide). Granulomatosis with polyangiitis or microscopic polyangiitis:Induction therapy: 375 mg/m2 once weekly for 4 doses or 1 g once every 2 weeks for 2 doses; for either dosing regimen, administer in combination with a systemic glucocorticoid. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Hypersensitivity to rituximab and any excipients or proteins in this product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Common Dermatologic: Pruritus (10% to 14% ) Gastrointestinal: Nausea (23% ) Hematologic: Anemia, All Grades (8% to 35% ), Lymphocytopenia, All Grades (48% ) Neurologic: Asthenia (26% ), Headache (19% ) Other: Fever (53% ), Shivering (33% ) Serious Cardiovascular: Cardiogenic shock, Hypotension (10% ), Myocardial infarction, Ventricular fibrillation Dermatologic: Lichen simplex chronicus, Pemphigus paraneoplastica, Stevens-Johnson syndrome, Toxic epidermal necrolysis Gastrointestinal: Gastrointestinal perforation Hematologic: Anemia, Grade 3 or 4 (3% ), Leukopenia, Grade 3 or 4 (4% ), Lymphocytopenia, Grade 3 or 4 (40% ), Neutropenia, Grade 3 or 4 (4% to 6% ), Pancytopenia, Grade 3 or 4, Thrombocytopenia, Grade 3 or 4 (2%) Hepatic: Reactivation of hepatitis B viral hepatitis Neurologic: Progressive multifocal leukoencephalopathy Renal: Nephrotoxicity Respiratory: Bronchospasm (8% ), Pulmonary toxicity (18% ) Other: Angioedema (11% ), Infectious disease (19% to 37% ), Infusion reaction (Equal to or greater than 25% ), Tumor lysis syndrome                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Pregnancy          | Human Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| More Info          | [UpToDate](https://www.uptodate.com/contents/rituximab-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

